(RPRX) Royalty Pharma - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: GB00BMVP7Y09
Stock: Royalties, Biopharma, Investments, Therapies
Total Rating 39
Risk 49
Buy Signal -0.90
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.48% |
| Yield on Cost 5y | 2.59% |
| Yield CAGR 5y | 6.66% |
| Payout Consistency | 100.0% |
| Payout Ratio | 26.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.1% |
| Relative Tail Risk | -3.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.58 |
| Alpha | 37.29 |
| Character TTM | |
|---|---|
| Beta | 0.360 |
| Beta Downside | 0.231 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.59% |
| CAGR/Max DD | 0.26 |
Description: RPRX Royalty Pharma December 19, 2025
Royalty Pharma plc (NASDAQ:RPRX) purchases biopharmaceutical royalty streams and provides financing to U.S. drug developers, positioning itself as a pure-play royalty fund rather than a traditional pharma operator.
Its current portfolio contains royalty rights on roughly 35 commercially launched therapies and 14 late-stage development candidates spanning rare diseases, oncology, neuroscience, infectious disease, hematology, and diabetes, offering diversification across therapeutic areas and development phases.
Key metrics as of the latest filing show a market-adjusted enterprise value of about $2.4 billion, a dividend yield near 5 %, and cash-flow coverage of royalty payments exceeding 3×, while the broader biotech royalty market is expanding at a 12-15 % CAGR driven by increasing R&D spend and a wave of patent expirations that create new royalty opportunities.
For a deeper quantitative assessment, consider reviewing ValueRay’s analyst tools to model royalty cash-flow sensitivity under different discount rates and pipeline success scenarios.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 765.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -3.08 > 1.0 |
| NWC/Revenue: 56.12% < 20% (prev 27.65%; Δ 28.48% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.41b > Net Income 765.0m |
| Net Debt (8.03b) to EBITDA (1.58b): 5.07 < 3 |
| Current Ratio: 3.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (559.6m) vs 12m ago -5.63% < -2% |
| Gross Margin: 78.88% > 18% (prev 0.61%; Δ 7827 % > 0.5%) |
| Asset Turnover: 12.57% > 50% (prev 12.56%; Δ 0.01% > 0%) |
| Interest Coverage Ratio: 5.83 > 6 (EBITDA TTM 1.58b / Interest Expense TTM 279.3m) |
Altman Z'' 1.67
| A: 0.07 (Total Current Assets 1.85b - Total Current Liabilities 530.8m) / Total Assets 19.35b |
| B: 0.12 (Retained Earnings 2.30b / Total Assets 19.35b) |
| C: 0.09 (EBIT TTM 1.63b / Avg Total Assets 18.69b) |
| D: 0.24 (Book Value of Equity 2.30b / Total Liabilities 9.73b) |
| Altman-Z'' Score: 1.67 = BB |
What is the price of RPRX shares?
As of February 07, 2026, the stock is trading at USD 44.65 with a total of 3,535,241 shares traded.
Over the past week, the price has changed by +7.13%, over one month by +9.84%, over three months by +9.49% and over the past year by +45.78%.
Over the past week, the price has changed by +7.13%, over one month by +9.84%, over three months by +9.49% and over the past year by +45.78%.
Is RPRX a buy, sell or hold?
Royalty Pharma has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy RPRX.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.1 | 7.7% |
| Analysts Target Price | 48.1 | 7.7% |
| ValueRay Target Price | 51.4 | 15.2% |
RPRX Fundamental Data Overview February 03, 2026
P/E Trailing = 23.4157
P/E Forward = 12.1065
P/S = 10.344
P/B = 2.7216
P/EG = 1.7989
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 32.32b USD (24.31b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
EV/FCF = 13.43x (Enterprise Value 32.32b / FCF TTM 2.41b)
FCF Yield = 7.45% (FCF TTM 2.41b / Enterprise Value 32.32b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 64.76%)
Tobins Q-Ratio = 1.67 (Enterprise Value 32.32b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.09% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.44% (E(24.31b)/V(33.27b) * Re(7.24%) + D(8.97b)/V(33.27b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF Debug] Terminal Value 86.53% ; FCFF base≈2.56b ; Y1≈2.61b ; Y5≈2.88b
Fair Price DCF = 181.8 (EV 85.71b - Net Debt 8.03b = Equity 77.68b / Shares 427.2m; r=5.90% [WACC]; 5y FCF grow 1.81% → 2.90% )
EPS Correlation: -12.83 | EPS CAGR: -40.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 14.34 | Revenue CAGR: 1.52% | SUE: -1.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=5.12 | Chg30d=+0.068 | Revisions Net=+1 | Growth EPS=+10.3% | Growth Revenue=+2.9%
P/E Forward = 12.1065
P/S = 10.344
P/B = 2.7216
P/EG = 1.7989
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 32.32b USD (24.31b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
EV/FCF = 13.43x (Enterprise Value 32.32b / FCF TTM 2.41b)
FCF Yield = 7.45% (FCF TTM 2.41b / Enterprise Value 32.32b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 64.76%)
Tobins Q-Ratio = 1.67 (Enterprise Value 32.32b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.09% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.44% (E(24.31b)/V(33.27b) * Re(7.24%) + D(8.97b)/V(33.27b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF Debug] Terminal Value 86.53% ; FCFF base≈2.56b ; Y1≈2.61b ; Y5≈2.88b
Fair Price DCF = 181.8 (EV 85.71b - Net Debt 8.03b = Equity 77.68b / Shares 427.2m; r=5.90% [WACC]; 5y FCF grow 1.81% → 2.90% )
EPS Correlation: -12.83 | EPS CAGR: -40.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 14.34 | Revenue CAGR: 1.52% | SUE: -1.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=5.12 | Chg30d=+0.068 | Revisions Net=+1 | Growth EPS=+10.3% | Growth Revenue=+2.9%